NIIMBL Unveils 3 New Vaccine Manufacturing Projects

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Why Custom Tin Containers Are Reshaping Medicine & Supplement Packaging

In an industry driven by both compliance and consumer...

Sarclisa by Sanofi has EC Approval to Treat Multiple Myeloma

In order to treat multiple myeloma in adults, Sarclisa...

US Levies 15% Tariff on EU for Pharmaceutical Products

The European Union is going to pay the US...

EU-US Trade Deal Taking Shape as Pharma Tariffs Materialize

Finally, the Trump administration’s much-animated tariffs on pharmaceutical imports...

The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) has announced approximately $1.7 million in planned project activities through the Institute’s Global Health Fund (GHF) Project Call 6.1G for three new projects focused on the development of in vitro potency assays for vaccines being produced by mRNA and/or viral vector technologies.

These projects were selected to best align with key focus areas identified by NIIMBL and the Bill and Melinda Gates Foundation (BMGF) to address industry needs. The Global Health Fund was established by NIIMBL with funding contributed by BMGF to develop and implement innovative technologies for vaccine and biological manufacturing that will accelerate development timelines and lower the cost of manufacturing, all in furtherance of BMGF’s charitable objectives.

“NIIMBL is looking forward to adding these key projects to our GHF portfolio. These projects will allow us to further advance innovation in vaccine manufacturing, particularly around potency assays that are important for characterization of key quality aspects of vaccines,” said Chris Roberts, associate institute director, NIIMBL. “The recent pandemic highlighted several needs for vaccine development and manufacturing across multiple potential vaccine targets. These projects will make significant advances for vaccine manufacturing.

NIIMBL has awarded approximately 142 technical, workforce development, and Global Health Fund projects through the Project Call process with a total project investment of over $111 million since 2017 when the Institute launched. The NIIMBL community is comprised of more than 200 members from academia, industry, government, and non-profit organizations. They all share the common goal of advancing biopharmaceutical manufacturing.

 

Latest stories

Related stories

Why Custom Tin Containers Are Reshaping Medicine & Supplement Packaging

In an industry driven by both compliance and consumer...

Sarclisa by Sanofi has EC Approval to Treat Multiple Myeloma

In order to treat multiple myeloma in adults, Sarclisa...

US Levies 15% Tariff on EU for Pharmaceutical Products

The European Union is going to pay the US...

EU-US Trade Deal Taking Shape as Pharma Tariffs Materialize

Finally, the Trump administration’s much-animated tariffs on pharmaceutical imports...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back